Selank

Selank is a defined synthetic heptapeptide related to tuftsin. The field combines small clinical reports with neural signalling experiments, and those forms of evidence should be evaluated separately^1,3,5.

The presence of comparative human studies earns a controlled-human tier in this framework. It does not establish robust replicated efficacy, a general focus benefit or the absence of dependence and adverse effects under all conditions^1,2,7.

Tuftsin provided the starting motif for Selank’s peptide design. Its defined sequence is different from Semax, which was developed from an ACTH-associated fragment⁵.

Subsequent research examined anxiety-related behavior, inhibitory neurotransmission and peptide metabolism. This mixed program supports mechanistic investigation but does not produce a single settled human target^1,3,5.

Membrane experiments found that Selank changed GABA-associated binding in a concentration- and co-exposure-dependent manner. Those results support a modulation hypothesis rather than a claim of selective clinical action at a definitively established receptor site⁵.

Rat hippocampal slices showed changes in spontaneous inhibitory synaptic activity. Gene-expression work in rats and cultured neuroblastoma cells varied by context, reinforcing that a laboratory GABA association is not a full clinical mechanism^3,4,6.

An early report compared 30 Selank recipients with 32 medazepam recipients among patients with generalized anxiety disorder or neurasthenia. It reported similar anxiolytic effects, but the indexed abstract does not establish the detailed randomization, masking or equivalence-testing needed for a strong equivalence claim¹.

Another report compared 30 people receiving phenazepam alone with 40 receiving Selank plus phenazepam. Findings about tolerability and clinical response belong to adjunctive treatment in that sample, not proof that Selank is universally nonsedating or superior².

The rat transcription experiment examined 84 neurotransmission-associated genes and found time-dependent changes. That is an exploratory pathway measurement, not an improvement score for human attention³.

In cultured cells, Selank alone did not alter the measured gene-expression panel, while combinations modified responses to other compounds. This difference cautions against presenting a uniformly activating or calming molecular effect⁶.

Small comparative reports provide some tolerability observations but cannot estimate uncommon adverse effects or prove long-term safety. FDA identifies limited safety information and possible aggregation or impurity-related immunogenicity^1,2,7.

Concurrent sedatives, psychiatric medicines and alcohol deserve review because the mechanistic work includes interactions with other GABA-associated compounds. Pregnancy, breastfeeding and injectable-route exposure remain insufficiently characterized^5,6,7.

Clinical reports concern peptide drug preparations in defined settings, while this catalog vial’s final form and route are not specified^1,2. Confirm whether the prescribed product is an intranasal liquid or an injection preparation; do not transfer route-specific assumptions.

The catalog specifies vial content, not a verified final formulation or storage specification. A lyophilized preparation requires the pharmacy-specified compatible diluent; a ready-to-use liquid does not. Follow the dispensing label for refrigeration, light protection and the beyond-use date, and use aseptic technique with a new sterile needle and syringe⁸. Dosing is set by your provider.